Cover Image
市場調查報告書

白細胞介素10 (細胞激素合成抑制因子 (CISF) 或IL10):開發中產品分析

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363135
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素10 (細胞激素合成抑制因子 (CISF) 或IL10):開發中產品分析 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 77 Pages
簡介

本報告提供全球各國的白細胞介素10 (細胞激素合成抑制因子 (CISF) 或IL10)的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 白細胞介素10 (細胞激素合成抑制因子 (CISF) 或IL10)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 不同症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學·研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • BioMAS Ltd.
    • Biotest AG
    • enGene, Inc
    • Intrexon Corporation
    • LEO Pharma A/S
    • Merck & Co., Inc.
    • P2D Bioscience
    • Pfizer Inc.
    • SK Biopharmaceuticals Co., Ltd.
  • 藥物簡介
    • AM-0010
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • ANV-103
    • AS-101
    • Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes
    • Biologic to Target Gluten and IL-10 for Celiac Disease
    • Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes
    • BT-063
    • Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation
    • Dekavil
    • EG-10
    • EG-12
    • Elmyelin
    • Gene Therapy to Activate Interleukin 10 for Atherosclerosis
    • Gene Therapy to Activate Interleukin-10 for ALS
    • LEO-32731
    • MK-1966
    • PD-2244
    • SKL-16036
    • Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease
    • Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases
    • XT-101
    • XT-150
  • 暫停開發的產品
  • 開發中止的產品
  • 值得注意的最新趨勢·新聞稿 (全13件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0597TDB

Summary

Global Markets Direct's, 'Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
  • The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview
  • Therapeutics Development
    • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development
    • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area
    • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development
    • Aptevo Therapeutics Inc
    • ARMO Biosciences, Inc.
    • BioMAS Ltd.
    • Biotest AG
    • enGene, Inc
    • Intrexon Corporation
    • LEO Pharma A/S
    • Merck & Co., Inc.
    • P2D Bioscience
    • Pfizer Inc.
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles
    • AM-0010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANV-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BT-063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTLA-4 X mono-IL-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dekavil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Elmyelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LEO-32731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1966 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-2244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XT-150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases
    • Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • Aug 15, 2016: ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology
    • Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers
    • Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016
    • Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis
    • Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences
    • Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference
    • Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences
    • Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus
    • Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action
    • May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting
    • Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences
    • Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
    • Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes
    • Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Pipeline by ARMO Biosciences, Inc., H2 2016
  • Pipeline by BioMAS Ltd., H2 2016
  • Pipeline by Biotest AG, H2 2016
  • Pipeline by enGene, Inc, H2 2016
  • Pipeline by Intrexon Corporation, H2 2016
  • Pipeline by LEO Pharma A/S, H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by P2D Bioscience, H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top